Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join our Virtual Triathlon Challenge and swim, cycle and run while raising money to fund Breakthrough T1D’s life-changing type 1 research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > New research highlights the effectiveness of immune therapies for type 1 diabetes
In a research paper published in the Lancet journal, an international team of researchers combined data from 21 clinical trials of immune therapies, or immunotherapies, which revealed the incredible potential of immunotherapy to treat people newly diagnosed with type 1 diabetes.
Clinical trials have demonstrated that immunotherapies can interfere with the destruction of insulin-producing cells, called beta cells. Preserving beta cells allows people developing type 1 diabetes to keep making their own insulin for longer. If people with type 1 can produce even a small amount of insulin, their type 1 may be considerably easier to manage, a phenomenon known as the honeymoon phase.
The research group includes leading immunologists from Breakthrough T1D UK, Cardiff University, Critical Path Institute, University of Alberta, Colorado University and the pharmaceutical industry including JDRF-funded researcher Professor Colin Dayan. Professor Colin Dayan from Cardiff University said: “This research supports the role of immunotherapy, focusing on preventing the autoimmune destruction of insulin producing cells, rather than simply relying on insulin to treat the resulting insulin deficiency. Potentially screening programs could detect people at high risk of type 1 diabetes, and these treatments could be used even earlier with the ultimate aim of preventing childhood type 1 diabetes.”
Currently, immune therapies can delay the onset of type 1 diabetes and the need for insulin treatment. This delay is crucial to limit the prevalence of type 1 in childhood, where the condition can be more challenging to manage due to the hormones involved in puberty. Giving children their childhood back is an exciting possibility thanks to immunotherapy drugs. Combining immune therapies and fine-tuning the drugs offers hope that we could one day halt the immune attack completely.
C-peptide (short for connecting peptide) is needed to make insulin. Beta cells release C-peptide with insulin in equal amounts, but insulin is used quickly so it is difficult to measure. Measuring the amount of C-peptide in a blood sample is an accurate measure of how much insulin beta cells are releasing.
This new research established the importance of C-peptide as a biological marker of type 1. This offers an effective tool to measure the success of clinical trials and understand how well people are managing their type 1.
The research heralds a new era of type 1 diabetes treatment. We must now help get these powerful drugs into the hands of people who can benefit from them. Joint first author Dr Kimberly Collins, joint lead researcher from the Critical Path Institute said: “The data and analysis performed in this exciting project have provided the basis for an invaluable clinical trial simulation tool to promote faster and more efficient clinical trials in this space.”
Sana Biotechnology, a US-based biotech company, has released clinical data showing that the first person receiving engineered islets from deceased donors is now producing insulin without the need for immunosuppressive drugs.
Our highlights from a year full of breakthroughs in type 1 diabetes research and advocacy.
We’ve awarded four new grants to UK researchers to help improve lives and develop cures for people living with type 1 diabetes.
The framework aims to encourage UK researchers to consider different sexes (biological attributes) and genders (roles, behaviours and identity in society) to address gaps in health data.
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.